News
All
This breakthrough cancer treatment could target deadly cells and CURE killer disease
Read moreInterrogation of individual intratumoral B lymphocytes from lung cancer patients for molecular target discovery.
Campa MJ, Moody MA, Zhang R, Liao HX, Gottlin EB, Patz EF Jr.
Cancer Immunol Immunother. 2016 Feb;65(2):171-80. doi:
10.1007/s00262-015-1787-0. Epub 2016 Jan 6.
PMID: 26739486 [PubMed – indexed for MEDLINE]
Read moreComplement Factor H Antibodies from Lung Cancer Patients Induce Complement-Dependent Lysis of Tumor Cells, Suggesting a Novel Immunotherapeutic Strategy.
Campa MJ, Gottlin EB, Bushey RT, Patz EF Jr.
Cancer Immunol Res. 2015 Dec;3(12):1325-32. doi:
10.1158/2326-6066.CIR-15-0122. Epub 2015 Jul 27.
PMID: 26216416 [PubMed – indexed for MEDLINE] Free Article
Read moreThe Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer.
Gottlin EB, Bentley RC, Campa MJ, Pisetsky DS, Herndon JE 2nd, Patz EF
Jr..
J Thorac Oncol. 2011 Oct;6(10):1687-90. doi:
10.1097/JTO.0b013e3182217bec..
PMID: 21642860 [PubMed – indexed for MEDLINE] Free Article
Read moreComplement factor H autoantibodies are associated with early stage NSCLC.
Amornsiripanitch N, Hong S, Campa MJ, Frank MM, Gottlin EB, Patz EF Jr.
Clin Cancer Res. 2010 Jun 15;16(12):3226-31. doi:
10.1158/1078-0432.CCR-10-0321. Epub 2010 Jun 1.
PMID: 20515868 [PubMed – indexed for MEDLINE] Free PMC Article
Read moreTumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients.
Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi MB, Harpole DH Jr,
Patz EF Jr.
Cancer. 2006 Dec 15;107(12):2866-72.
PMID: 17099880 [PubMed – indexed for MEDLINE] Free Article
Read more